logo
logo
logo
logo
  • News
  • Approach
  • ESG
  • Portfolio
  • Team
  • Tech Investments
  • Contact

Wellington Partners’s portfolio company Themis to be acquired by MSD

26. May 2020
|In Portfolio News
|By eazee-designstudio

Wellington Partners’s portfolio company Themis to be acquired by MSD

26. May 2020
|In Portfolio News
|By eazee-designstudio

Themis and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications.

  • Prev
  • Next

© 2022 Wellington Partners. All rights reserved  |  Imprint  |  Privacy Policy | SFDR Disclosures | PRIIPS

Privacy Preference Center

Privacy Preferences